Terumo Corporation (TSE: 4543) announces it has been included in the FTSE4Good Index Series and the FTSE Blossom Japan Index for the first time.
Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indexes are used by a wide variety of market participants to create and assess responsible investment funds and other products.
The FTSE Blossom Japan Index is designed as an industry neutral benchmark that reflects the performance of companies demonstrating strong ESG practices in Japan.
FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change. Businesses included in the FTSE4Good Index Series and the FTSE Blossom Japan Index meet a variety of environmental, social and governance criteria.
Since its foundation in 1921, Terumo has continued to bring new value to healthcare by addressing and resolving issues faced by medical settings. The Group Mission "Contributing to Society through Healthcare" has guided the company throughout this process. In addition to providing a stable supply of high-quality medical devices and services to patients and medical professionals throughout the world, Terumo is actively engaged in ESG efforts in order to respond to a wide variety of expectations from various stakeholders and society at large.
Most recently, in response to the global COVID-19 pandemic, Terumo Group companies mustered their collective capabilities to ensure stable supply of products while contributing to the prevention and treatment of the disease.
As a company responsible for life and health, Terumo will continue to bring value to stakeholders by striving further to solve the numerous social and environmental issues surrounding healthcare; ultimately to achieve a sustainable and healthy society.
・ Sustainability | Terumo Global Website
・ FTSE4Good Index Series
・ FTSE Blossom Japan Index (Japanese)
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Corporate Communication Dept., Terumo Corporation
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.